Indeed, directly targeting HER2 amplification, EGFR and BRAF mutations, or the BCR-ABL fusion kinase, transformed the treatment of breast and lung cancers, melanoma, and chronic myelogenous leukaemias, respectively (1–4). This evidence concerns the gene EGFR and lung carcinoma.